JPRN-UMIN000028366已完成1 期
A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. - A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with the following medical histories. 1)Patients who are being suffered from squamous cell carcinoma except more than one year has passed without relapses following surgical operations. 2)Patients with severe allergic reactions such as shock and/or anaphylaxis clinical symptoms 3)Patients with skin hypersensitivities against topically applied medicines. 4)Patients with allergies against xenogeneic proteins 5)Patients with allergies against penicillin, streptomycin and/or amphotericin B. 2) Patients with the following complications. 1) Severe functional failures in the liver, heart and/or lung. (3)Patients who underwent the following conditions within one year of the day of initiation of this study. 1) Drug abuses 2) Alcohol dependencies (4)Patients who participated in other clinical trials and/or intervention studies within 4 months (120 days) of the day of initiation of this study. (5)Patients who are considered not suitable for the study by principal investigator.
研究者
相似试验
已完成
Unknown
A Clinical Study to determine Safety, Efficacy, In-Use Tolerability Study of HDSC-022209.CTRI/2023/03/050239Himalaya Wellness Company42
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-GBOctapharma AG5
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-FROctapharma AG5
进行中（未招募）
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-DEOctapharma AG45
已完成
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersOther immunodeficienciesISRCTN63491981Octapharma AG (Switzerland)45